nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

01.04.2013

A Cutting Edge Overview: Psoriatic Disease

verfasst von: Siba P. Raychaudhuri

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Psoriasis is a lifelong skin disease, affecting about 2% of the global population. Generalized involvement of the body (erythroderma), extensive pustular lesions, and an associated arthritis known as psoriatic arthritis (PsA) are severe complications of psoriasis. Genetic, immunologic, and environmental factors contribute to its pathogenesis. A complete understanding of the pathogenesis of psoriasis and psoriatic arthritis is lacking. Cytokines, chemokines, adhesion molecules, growth factors like NGF, neuropeptides, and T cell receptors all act in an integrated way to evolve into unique inflammatory and proliferative processes typical of psoriasis and PsA. Management of psoriasis requires exemplary skin care along with careful monitoring of arrays of comorbidities which includes arthritis and coronary artery disease. In many ways, psoriasis can be considered a model autoimmune disease. This statement itself is ironic considering that it was not recognized as immune mediated until relatively recently. Fortunately, the immunobiology has made enormous strides and there are now excellent therapeutic options for patients. In this thematic review, we have attempted to provide summaries of not only basic science and clinical research, but also an overview of future research directions.

Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866–873PubMedCrossRef

Scarpa R, Ayala F, Caporaso N, Olivieri I (2006) Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 33:210–212PubMed

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef

Kaye JA, Li L, Jick SS (2008) Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159:895–802PubMedCrossRef

Stuart PE, Nair RP, Ellinghaus E et al (2010) Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 42:1000–1004PubMedCrossRef

Nickoloff BJ, Schröder JM, von den Driesch P et al (2000) Is psoriasis a T-cell disease? Exp Dermatol 9:359–375PubMedCrossRef

Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314–J321PubMedCrossRef

Nickoloff BJ (2006) Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 12:102–106PubMedCrossRef

Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263–271PubMedCrossRef

10.

Hertle MD, Kubler MD, Leigh IM, Watt FM (1992) Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J Clin Invest 89:1892–1901PubMedCrossRef

11.

Sa SM, Valdez PA, Wu J et al (2007) The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178:2229–2240PubMed

12.

Wolk K, Witte E, Warszawska K et al (2009) The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 39:3570–3581PubMedCrossRef

13.

Raychaudhuri SP, Raychaudhuri SK, Genovese MC (2012) L-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 359:419–429PubMedCrossRef

14.

Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172:961–971PubMedCrossRef

15.

Raychaudhuri SP, Jiang WY, Farber EM, Schall TJ, Ruff MR, Pert CB (1999) Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 79:9–11PubMedCrossRef

16.

Romanowska M, al Yacoub N, Seidel H et al (2008) PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor. J Invest Dermatol 128:110–124PubMedCrossRef

17.

Széles L, Töröcsik D, Nagy L (2007) PPAR gamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 1771:1014–1030PubMedCrossRef

18.

al Yacoub N, Romanowska M, Krauss S, Schweiger S, Foerster J (2008) PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells. J Invest Dermatol 128:1940–1949PubMedCrossRef

19.

Sagoo GS, Tazi-Ahnini R, Barker JW et al (2004) Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol 122:1401–1405PubMedCrossRef

20.

Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D (1998) Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol 110:958–960PubMedCrossRef

21.

Veal CD, Clough RL, Barber RC et al (2001) Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 38:7–13PubMedCrossRef

22.

Capon F, Semprini S, Chimenti S et al (2001) Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol 116:728–730PubMedCrossRef

23.

Nair RP, Duffin KC, Helms C et al (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41:199–204PubMedCrossRef

24.

Zhang XJ, Huang W, Yang S et al (2009) Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 41:205–210PubMedCrossRef

25.

Campalani E, Allen MH, Fairhurst D et al (2006) Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 154:345–352PubMedCrossRef

26.

Gottlieb AB, Lebwohl M, Shirin S et al (2000) Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 43:595–504PubMedCrossRef

27.

Wrone-Smith T, Nickoloff BJ (1996) Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878–1887PubMedCrossRef

28.

Eyerich S, Eyerich K, Pennino D et al (2009) Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 119:3573–3585PubMed

29.

Caruso R, Botti E, Sarra M et al (2009) Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 15:1013–1015PubMedCrossRef

30.

Di Cesare A, Di Meglio P, Nestle FO (2009) The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129:1339–1350PubMedCrossRef

31.

Shibata S, Tada Y, Kanda N et al (2010) Possible roles of IL-27 in the pathogenesis of psoriasis. J Invest Dermatol 130:1034–1039PubMedCrossRef

32.

Lowes MA, Chamian F, Abello MV et al (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci 102:19057–19062PubMedCrossRef

33.

Wang H, Peters T, Kess D et al (2006) Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116:2105–2114PubMedCrossRef

34.

Braverman IM, Yen A (1977) Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 68:53–60PubMedCrossRef

35.

Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ (1999) Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 42:1481–1484PubMedCrossRef

36.

Creamer D, Sullivan D, Bicknell R, Barker J (2002) Angiogenesis in psoriasis. Angiogenesis 5:231–236PubMedCrossRef

37.

Libby P, Paul M, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143PubMedCrossRef

38.

Zaman AG, Helft G, Worthley SG, Badimon JJ (2000) The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149:251–266PubMedCrossRef

39.

Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP (2010) Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 8:331–334PubMedCrossRef

40.

Bizzaro N, Tozzoli R, Shoenfeld Y (2007) Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 56:1736–1744PubMedCrossRef

41.

Hershko AY, Naparstek Y (2006) Autoimmunity in the era of genomics and proteomics. Autoimmun Rev 5:230–233PubMedCrossRef

42.

Hoffmann MH, Trembleau S, Muller S, Steiner G (2010) Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 34:J178–J206PubMedCrossRef

43.

Mackay IR (2010) Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 9:A251–A258PubMedCrossRef

44.

Martin PI, Malizia AI, Rewald E (2008) A propos time and autoimmunity. Clin Rev Allergy Immunol 34:380–384PubMedCrossRef

45.

Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H (2010) Light, including ultraviolet. J Autoimmun 34:J247–J257PubMedCrossRef

46.

Chen M, Daha MR, Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:J276–J286PubMedCrossRef

47.

Selmi C (2010) The worldwide gradient of autoimmune conditions. Autoimmun Rev 9:A247–A250PubMedCrossRef

48.

Youinou P, Pers JO, Gershwin ME, Shoenfeld Y (2010) Geo-epidemiology and autoimmunity. J Autoimmun 34:J163–J167PubMedCrossRef

49.

Selmi C, Tsuneyama K (2010) Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 9:A267–A270PubMedCrossRef

50.

Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34:J168–J177PubMedCrossRef

51.

Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31:325–330PubMedCrossRef

52.

Stojanovich L (2010) Stress and autoimmunity. Autoimmun Rev 9:A271–A276PubMedCrossRef

53.

Tobon GJ, Youinou P, Saraux A (2010) The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun Rev 9:A288–A292PubMedCrossRef

54.

Chen M, Kallenberg CG (2010) The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 9:A293–A298PubMedCrossRef

55.

Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9:A325–A329PubMedCrossRef

56.

Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH (2010) Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 9:A400–A405PubMedCrossRef

57.

Round JL, O’Connell RM, Mazmanian SK (2010) Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 34:J220–J225PubMedCrossRef

58.

Sands J, Tuscano JM (2010) Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 9:A335–A341PubMedCrossRef

59.

Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity—autoantibodies versus autoimmune disease. Autoimmun Rev 9:A259–A266PubMedCrossRef

60.

Logan I, Bowlus CL (2010) The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 9:A372–A378PubMedCrossRef

61.

Meyer N, Misery L (2010) Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 9:A379–A382PubMedCrossRef

62.

Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010) Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 34:J226–J233PubMedCrossRef

63.

Borchers AT, Naguwa SM, Keen CL, Gershwin ME (2010) The implications of autoimmunity and pregnancy. J Autoimmun 34:J287–J299PubMedCrossRef

64.

Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:A277–A287PubMedCrossRef

65.

Borchers AT, Uibo R, Gershwin ME (2010) The geoepidemiology of type 1 diabetes. Autoimmun Rev 9:A355–A365PubMedCrossRef

66.

Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34:J207–J219PubMedCrossRef

67.

Chang C (2010) The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 34:J234–J246PubMedCrossRef

68.

Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34:J258–J265PubMedCrossRef

69.

Langham S, Langham J, Goertz HP, Ratcliffe M (2011) Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: a systemic and critical review. BMC Med Res Methodol 11:32PubMedCrossRef

70.

Slutsky JB, Clark RA, Remedios AA, Klein PA (2010) An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J Drugs Dermatol 9:1258–1264PubMed

71.

O’Neill JL, Feldman SR (2010) Vitamine D analogue-based therapies for psoriasis. Drugs Today (Barc) 46:351–360

72.

Seminara NM, Gelfand JM (2010) Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg 29:16–19PubMedCrossRef

73.

Baraliakos X, Braun J (2010) Anti-TNF-alpha therapy with infliximab in spondyloarthritides. Expert Rev Clin Immunol 6:9–19PubMedCrossRef

74.

Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME (2011) Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 37:273–288PubMedCrossRef

75.

Piconese S, Costanza M, Tripodo C, Sangaletti S, Musio S, Pittoni P, Poilani PL, Burocchi A, Passafaro AL, Gorzanelli A, Vitali C, Chiodoni C, Barnaba V, Pedotti R, Colombo MP (2011) The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. J Autoimmun 37:300–310PubMedCrossRef

76.

Dagur PK, Biancotto A, Wei L, Sen HN, Yao M, Strober W, Nussenblatt RB, Philip McCoy J Jr (2011) MCAM-expressing CD4(+) T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases. J Autoimmun 37:319–327PubMedCrossRef

77.

Kaminski S, Hermann-Kleiter N, Meisel M, Thuille N, Cronin S, Hara H, Fresser F, Penninger JM, Baier G (2011) Coronin 1A is an essential regulator of the TGFβ receptor/SMAD3 signaling pathway in Th17 CD4(+) T cells. J Autoimmun 37:198–208PubMedCrossRef

78.

Wang YL, Chou FC, Chen SJ, Lin SH, Chang DM, Sytwu HK (2011) Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases—an unrevealed role in downregulation of Th17 cells. J Autoimmun 37:160–170PubMedCrossRef

79.

Baugh M, Black D, Westwood P, Kinghorn E et al (2011) Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 36:201–209PubMedCrossRef

80.

Hickman-Brecks CL, Racz JL, Meyer DM, LaBranche TP, Allen PM (2011) Th17 cells can provide B cell help in autoantibody induced arthritis. J Autoimmun 36:65–75PubMedCrossRef

81.

Oo YH, Adams DH (2010) The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun 34:45–54PubMedCrossRef

82.

Reich A, Szepietowski JC (2011) Health-related quality of life in patients with nail disorders. Am J Clin Dermatol 12:313–320PubMedCrossRef

Titel: A Cutting Edge Overview: Psoriatic Disease
verfasst von: Siba P. Raychaudhuri
Publikationsdatum: 01.04.2013
Verlag: Humana Press Inc
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 2/2013
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-012-8309-z

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

A Cutting Edge Overview: Psoriatic Disease

Abstract

Neu im Fachgebiet HNO

Akuter Schwindel: Wann lohnt sich eine MRT?

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

The Genetics of Psoriasis and Psoriatic Arthritis

Imaging in Psoriatic Arthritis

Type I Interferons: Beneficial in Th1 and Detrimental in Th17 Autoimmunity

Inflammation, Atherosclerosis, and Psoriasis

Psoriatic Arthritis: a Critical Review

Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring

Neu im Fachgebiet HNO

Akuter Schwindel: Wann lohnt sich eine MRT?

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Update HNO